4//SEC Filing
Stergiou Angelos M. 4
Accession 0001104659-20-034286
CIK 0001390478other
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 9:18 PM ET
Size
17.7 KB
Accession
0001104659-20-034286
Insider Transaction Report
Form 4
Stergiou Angelos M.
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2020-03-12+70,000→ 70,000 totalExercise: $1.89Exp: 2030-03-12→ Common Stock (70,000 underlying) - Award
Common Stock
2020-03-12+95,000→ 95,000 total
Footnotes (2)
- [F1]The reporting person received an award of 95,000 restricted stock units on March 12, 2020, which shall vest as follows: (i) 50% on meeting the primary endpoint in Phase 3 REGAL study, provided that if such endpoint is met prior to March 12, 2021, such vesting will not occur until March 12, 2021 and (ii) 50% upon approval by the FDA of galinpepimut-S.
- [F2]One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 12, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
Issuer
SELLAS Life Sciences Group, Inc.
CIK 0001390478
Entity typeother
Related Parties
1- filerCIK 0001724253
Filing Metadata
- Form type
- 4
- Filed
- Mar 15, 8:00 PM ET
- Accepted
- Mar 16, 9:18 PM ET
- Size
- 17.7 KB